Target intelligence / Profile preview

Insulin receptor (INSR) pre-mRNA CUG-binding protein 1 (CUG-BP1) splice-regulatory site (INSR exon 11 SRS)

Target
INSR exon 11 SRS
Molecular classification
RNA, Splice-regulatory element, Cis-acting RNA element
01

Overview

The Insulin receptor (INSR) pre-mRNA CUG-BP1 splice-regulatory site is a critical cis-acting RNA element located within the INSR transcript that governs the alternative splicing of exon 11 (Savkur et al., 2001, Nature Genetics). This site is primarily regulated by the antagonistic binding of CUG-binding protein 1 (CUG-BP1/CELF1) and Muscleblind-like 1 (MBNL1); CELF1 promotes the exclusion of exon 11 to produce the IR-A isoform, while MBNL1 promotes its inclusion to produce the IR-B isoform (Kuyumcu-Martinez et al., 2007, Molecular Cell). IR-B is the predominant isoform in adult metabolic tissues and possesses high affinity for insulin, whereas IR-A is a fetal isoform with lower metabolic signaling efficiency. In Myotonic Dystrophy Type 1 (DM1), the expansion of CUG repeats leads to the sequestration of MBNL1 and the stabilization of CELF1, resulting in an abnormal shift toward IR-A and subsequent insulin resistance (Paul et al., 2006, Journal of Biological Chemistry). Therapeutic strategies targeting this regulatory region, such as splice-switching antisense oligonucleotides (ASOs), aim to restore the balance of INSR isoforms by blocking CELF1 binding or promoting exon 11 inclusion (Wheeler et al., 2012, Nature). This target is a key focus for addressing the metabolic dysfunction associated with RNA-dominant neuromuscular disorders.

Other names
INSR exon 11 splice-regulatory elementCELF1 binding site on INSR pre-mRNAInsulin receptor exon 10-12 splice regionINSR pre-mRNA exon 11
02

Mechanism of action

Modulation of alternative splicing to promote the inclusion of exon 11 in the insulin receptor (INSR) mRNA, thereby increasing the expression of the IR-B isoform.

03

Biological functions

Alternative splicingRNA processingGlucose metabolism regulationSignal transduction
04

Disease associations

Myotonic dystrophy type 1Insulin resistanceMyotonic dystrophy type 2
05

Safety considerations

Off-target RNA bindingDelivery to skeletal musclePotential for unintended splicing changes in non-target genes
06

Interacting drugs

Antisense oligonucleotides (ASOs)

1 more in the full profile.

07

Biomarkers

IR-A/IR-B mRNA ratioCELF1 protein levelsMBNL1 sequestration status

Beyond the preview

Go deeper on Insulin receptor (INSR) pre-mRNA CUG-binding protein 1 (CUG-BP1) splice-regulatory site (INSR exon 11 SRS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insulin receptor (INSR) pre-mRNA CUG-binding protein 1 (CUG-BP1) splice-regulatory site (INSR exon 11 SRS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call